|
|
|
|
|||||
|
|
|
Phibro Animal Health PAHC delivered adjusted earnings per share (EPS) of 63 cents in the third quarter of fiscal 2025 compared with 31 cents in the year-ago quarter. The bottom line beat the Zacks Consensus Estimate by 21.1%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).
Without adjustments, GAAP EPS in the quarter was 51 cents compared with 21 cents in the prior-year period.
Net sales in the quarter totaled $347.8 million, up 23.8% from the year-ago quarter’s level. The figure missed the Zacks Consensus Estimate by 0.7%.
Following the announcement, PAHC shares rose 2.2% in after-hours trading yesterday.
The company conducts its operations via three segments — Animal Health, Mineral Nutrition and Performance Products.
In the third quarter of fiscal 2025, Animal Health’s net sales increased 42% to $258.4 million. The figure fell behind our model’s projection of $262.2 million.
Within the segment, net sales of medicated feed additives (MFAs) and others reflected 68% year-over-year growth, driven by incremental revenues of $77 million from sales of products from the Zoetis MFA portfolio acquired on Oct. 31, 2024.
Phibro Animal Health Corporation price-consensus-eps-surprise-chart | Phibro Animal Health Corporation Quote
Nutritional specialty product sales rose 8% due to increased domestic dairy demand and higher sales of microbial and companion animal products.
Net vaccine sales showed a year-over-year rise of 1%, primarily due to the continued growth of poultry products in Latin America.
Net sales in the Mineral Nutrition segment rose 4% year over year to $66.8 million due to higher average selling prices for zinc and trace minerals. Our model forecast was $71.4 million.
Net sales in the Performance Products segment rose 28% to $22.7 million due to higher demand for the ingredients used in personal care products. This also surpassed our model’s projection of $19 million.
Phibro’s fiscal third-quarter gross profit rose 31.3% year over year to $104.5 million. The gross margin contracted 20 basis points (bps) to 30.1% despite a 32.5% rise in the cost of goods sold.
Selling, general and administrative expenses in the reported quarter were $71.1 million, up 19.1% from the year-ago quarter’s levels. The operating profit totaled $33.4 million, an increase of 67.8% year over year. The operating margin expanded 204 bps year over year to 9.6%.
The company exited the third quarter of fiscal 2025 with cash and short-term investments of $70.4 million compared with $67.1 million at the end of the second quarter.
Cumulative net cash provided by operating activities at the end of the third quarter was $58.9 million compared with $59.2 million in the year-ago period.
For fiscal 2025, the company now expects net sales in the range of $1.26-$1.29 billion (earlier 1.25-$1.30 billion), implying 25% growth. The Zacks Consensus Estimate for the metric is pegged at $1.28 billion.
Adjusted EPS is expected in the range of $1.96-$2.09 (earlier 1.87-$2.01). The revised outlook indicates a 70% improvement compared to the earlier projected 63%. The Zacks Consensus Estimate is pegged at $1.94.
Phibro delivered an earnings beat and a revenue miss in the third quarter of fiscal 2025. However, the top line increased on a year-over-year basis. The company’s performance reflects the successful integration of the Zoetis MFA business and the initial positive impact of Phibro Forward initiatives, including benefits from actions such as SKU rationalization, enhanced procurement capabilities and manufacturing improvements. The Animal Health segment was a key growth driver. Additionally, the upbeat outlook for fiscal 2025 is encouraging.
Meanwhile, the contraction of the gross margin in the quarter does not bode well. The timing of orders in MFA and Other product sales and Vaccines also restricted growth. Phibro remains vigilant in the face of the evolving global trade landscape.
Phibro currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are AngioDynamics ANGO, Integer Holdings Corporation ITGR and Boston Scientific BSX.
AngioDynamics, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 composite’s 10.5% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 70.9%.
Integer Holdings, sporting a Zacks Rank #1 at present, posted a first-quarter 2025 adjusted EPS of $1.31, exceeding the Zacks Consensus Estimate by 3.1%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%.
ITGR has an estimated long-term earnings growth rate of 20.8% compared with the industry’s 14.3% growth. The company’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 2.8%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a first-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 11.9%. Revenues of $4.66 billion topped the Zacks Consensus Estimate by 2.3%.
BSX has an estimated 2025 earnings growth rate of 15.9% compared with the S&P 500 composite’s 11.9% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.8%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| 8 hours | |
| 11 hours | |
| 11 hours | |
| 11 hours | |
| 14 hours | |
| 14 hours | |
| 15 hours | |
| 15 hours | |
| 16 hours | |
| May-07 | |
| May-07 | |
| May-07 | |
| May-07 | |
| May-07 | |
| May-07 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite